Waldenstrom Macroglobulinemia

FDA Approves Imbruvica (Ibrutinib) for Waldenstrom Macroglobulinemia

The US Food and Drug Administration has approved Imbruvica (Ibrutinib) for people with Waldenstrom Macroglobulinemia.

Experts See Progress, Hope in Battle Against Childhood Cancers

Survival has improved dramatically for kids with cancer over the past 30 years.